title: Strategies for chemoprevention study of premalignancy and second primary tumors in the head and neck.
abstract: Recent strides in epidemiology (mutagen sensitivity assays) and basic molecular study of head and neck carcinogenesis are advancing chemoprevention in the head and neck. The clinical preventive activity of retinoids, the most studied and most active chemopreventive agents in this region, has been established in six randomized head and neck trials. Ongoing translational study of the p53 gene, nuclear retinoid receptors, and other cellular and molecular biomarkers will be necessary to achieve continuing progress in head and neck cancer chemoprevention.
authors.affiliation: University of Texas MD Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology, Houston 77030, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Lippman
authors.forename: M R
authors.initials: MR
authors.lastname: Spitz
authors.forename: M H
authors.initials: MH
authors.lastname: Huber
authors.forename: W K
authors.initials: WK
authors.lastname: Hong
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006258:Head and Neck Neoplasms / Q000517:prevention & control*; D006801:Humans; D016609:Neoplasms, Second Primary / Q000517:prevention & control*; D011230:Precancerous Conditions / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012176:Retinoids / Q000627:therapeutic use*
chemical_list: D016588:Anticarcinogenic Agents; D012176:Retinoids